DaVita Inc. (DVA): Price and Financial Metrics
DaVita Inc. (DVA)
Today's Latest Price: $89.70 USD
Updated Oct 20 4:00pm
Add DVA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 70 in Medical - Services
See all "A" rated Strong Buy stocks
DVA Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for DVA is 5.35 -- better than 92.07% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 8.38 for Davita Inc; that's greater than it is for 87.92% of US stocks.
- In terms of volatility of its share price, DVA is more volatile than only 1.67% of stocks we're observing.
- Stocks that are quantitatively similar to DVA, based on their financial statements, market capitalization, and price volatility, are AMCX, IRM, MTZ, CWST, and RRR.
- DVA's SEC filings can be seen here. And to visit Davita Inc's official web site, go to www.davita.com.
DVA Stock Price Chart Interactive Chart >
DVA Price/Volume Stats
| Current price | $89.70 | 52-week high | $92.67 |
| Prev. close | $89.56 | 52-week low | $56.99 |
| Day low | $89.41 | Volume | 617,125 |
| Day high | $90.68 | Avg. volume | 1,275,408 |
| 50-day MA | $86.61 | Dividend yield | N/A |
| 200-day MA | $81.31 | Market Cap | 10.94B |
DaVita Inc. (DVA) Company Bio
DaVita Healthcare Partners delivers dialysis services to patients with chronic kidney failure and end stage renal disease. The company was founded in 1994 and is based in Denver, Colorado.
DVA Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $89.70 | $290.31 | 224% |
Below please find a table outlining a discounted cash flow forecast for DVA, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Davita Inc ranked in the 70th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 225.83% on a DCF basis. The most interesting components of our discounted cash flow analysis for Davita Inc ended up being:
- As a business, DVA is generating more cash flow than 85.43% of positive cash flow stocks in the Healthcare.
- 46% of the company's capital comes from equity, which is greater than only 24.35% of stocks in our cash flow based forecasting set.
- Davita Inc's weighted average cost of capital (WACC) is 6%; for context, that number is higher than merely 1.53% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 218% |
| 1% | 221% |
| 2% | 224% |
| 3% | 227% |
| 4% | 231% |
| 5% | 234% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DVA, try PDEX, NVO, SGRY, ALXN, and LXRX.
Loading social stream, please wait...